BACKGROUND: Wilms tumour (WT) has various subtypes that are correlated with prognosis and require distinct therapy. Stromal predominant (SpWT) and epithelial WT (EpWT) have previously been associated with a good outcome. The current analysis describes the outcome and (tumour) characteristics of all patients with SpWT, EpWT, including highly differentiated epithelial type (HDET), treated according to the International Society of Pediatric Oncology (SIOP) 93-01 study. PROCEDURE: All children older than 6 months and below 18 years of age with localized or metastatic WT and intermediate risk (IR) histology or HDET treated with pre-operative chemotherapy were included in the present analysis. RESULTS: A total of 1,389 eligible patients had IR or HDET histology: 1% HDET, 4% EpWT, 10% SpWT, and 85% other IR. For EpWT/HDET, 93% had stage I/IIN-, 5-year EFS was 90.2% and overall survival of (OS) 98.4%, as compared to 84.0% and 92.5% in other IR histology (NS). Stage I EpWT/HDET had a significant better outcome than stage I of other IR. In SpWT 82% of cases had stage I/IIN-; 5-year EFS was 94.3% and OS 99.2%, significantly better compared to other IR histology. All patients with stage I are alive (2/149 relapses); 3/52 stage IIN-, 2/21 stage IIN+/III, and 6/12 stage IV patients relapsed (1 deceased per stage group). CONCLUSIONS: The good outcome for EpWT and SpWT generally is very good which may be related to low age and low stage in most cases. A reduction of treatment intensity and/or duration may be justified especially for low stage SpWT that has an EFS close to 100%. (c) 2010 Wiley-Liss, Inc.
BACKGROUND:Wilms tumour (WT) has various subtypes that are correlated with prognosis and require distinct therapy. Stromal predominant (SpWT) and epithelial WT (EpWT) have previously been associated with a good outcome. The current analysis describes the outcome and (tumour) characteristics of all patients with SpWT, EpWT, including highly differentiated epithelial type (HDET), treated according to the International Society of Pediatric Oncology (SIOP) 93-01 study. PROCEDURE: All children older than 6 months and below 18 years of age with localized or metastatic WT and intermediate risk (IR) histology or HDET treated with pre-operative chemotherapy were included in the present analysis. RESULTS: A total of 1,389 eligible patients had IR or HDET histology: 1% HDET, 4% EpWT, 10% SpWT, and 85% other IR. For EpWT/HDET, 93% had stage I/IIN-, 5-year EFS was 90.2% and overall survival of (OS) 98.4%, as compared to 84.0% and 92.5% in other IR histology (NS). Stage I EpWT/HDET had a significant better outcome than stage I of other IR. In SpWT 82% of cases had stage I/IIN-; 5-year EFS was 94.3% and OS 99.2%, significantly better compared to other IR histology. All patients with stage I are alive (2/149 relapses); 3/52 stage IIN-, 2/21 stage IIN+/III, and 6/12 stage IV patients relapsed (1 deceased per stage group). CONCLUSIONS: The good outcome for EpWT and SpWT generally is very good which may be related to low age and low stage in most cases. A reduction of treatment intensity and/or duration may be justified especially for low stage SpWT that has an EFS close to 100%. (c) 2010 Wiley-Liss, Inc.
Authors: Marry M van den Heuvel-Eibrink; Janna A Hol; Kathy Pritchard-Jones; Harm van Tinteren; Rhoikos Furtwängler; Arnauld C Verschuur; Gordan M Vujanic; Ivo Leuschner; Jesper Brok; Christian Rübe; Anne M Smets; Geert O Janssens; Jan Godzinski; Gema L Ramírez-Villar; Beatriz de Camargo; Heidi Segers; Paola Collini; Manfred Gessler; Christophe Bergeron; Filippo Spreafico; Norbert Graf Journal: Nat Rev Urol Date: 2017-10-31 Impact factor: 14.432
Authors: Linda Holmquist Mengelbier; Jenny Karlsson; David Lindgren; Ingrid Øra; Margareth Isaksson; Ildiko Frigyesi; Attila Frigyesi; Johannes Bras; Bengt Sandstedt; David Gisselsson Journal: Am J Pathol Date: 2010-09-16 Impact factor: 4.307
Authors: Murali M Chintagumpala; Elizabeth J Perlman; Brett Tornwall; Yueh-Yun Chi; Yeonil Kim; Fredric A Hoffer; John A Kalapurakal; Anne B Warwick; Robert C Shamberger; Geetika Khanna; Thomas E Hamilton; Kenneth W Gow; Arnold C Paulino; Eric J Gratias; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Michael L Ritchey; Paul E Grundy; Jeffrey S Dome; Peter F Ehrlich Journal: Cancer Date: 2022-04-05 Impact factor: 6.921
Authors: Lauren N Parsons; Elizabeth A Mullen; James I Geller; Yueh-Yun Chi; Geetika Khanna; Richard D Glick; Jennifer H Aldrink; Kelly L Vallance; Yeonil Kim; Conrad V Fernandez; Jeffrey S Dome; Elizabeth J Perlman Journal: Cancer Date: 2020-04-08 Impact factor: 6.860
Authors: Valentina Oliveira Provenzi; Rafael Fabiano Machado Rosa; Rosana Cardoso Manique Rosa; Adriana Vial Roehe; Pedro Paulo Albino dos Santos; Fabrízia Rennó Sodero Faulhaber; Ceres Andréia Vieira de Oliveira; Paulo Ricardo Gazzola Zen Journal: Rev Paul Pediatr Date: 2015-01-23